Charles R. Romp net worth and biography

Charles Romp Biography and Net Worth

EVP of Seagen

Chip leads our U.S. commercial organization and has over 27 years of biotechnology and pharmaceutical experience. Since joining Seagen to build our original ADCETRIS sales team, he has consistently provided decisive leadership and clear direction, and fostered a team culture that is true to our patient-centric values. Chip has continued to deliver strong results with the expansion of our portfolio to three brands: ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), and TUKYSA® (tucatinib). 

Previously, Chip was a National Sales Director for oncology and immunology products at Genentech, including Avastin® (bevacizumab) and Rituxan® (rituximab). While at Genentech, he also led deployment of the BioOncology sales forces. Earlier in his career, Chip was a Product Manager at GE Medical Systems and a pharmaceutical sales representative at Sankyo Park Davis and GlaxoSmithKline. 

Chip holds an M.B.A. from Saint Leo University (formerly Saint Leo College) and a B.A. from the University of Florida.  

What is Charles R. Romp's net worth?

The estimated net worth of Charles R. Romp is at least $11.68 million as of May 16th, 2023. Mr. Romp owns 59,777 shares of Seagen stock worth more than $11,684,610 as of June 7th. This net worth evaluation does not reflect any other assets that Mr. Romp may own. Learn More about Charles R. Romp's net worth.

How do I contact Charles R. Romp?

The corporate mailing address for Mr. Romp and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on Charles R. Romp's contact information.

Has Charles R. Romp been buying or selling shares of Seagen?

Charles R. Romp has not been actively trading shares of Seagen in the last ninety days. Learn More on Charles R. Romp's trading history.

Who are Seagen's active insiders?

Seagen's insider roster includes Roger Dansey (Insider), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Are insiders buying or selling shares of Seagen?

In the last twelve months, insiders at the biotechnology company sold shares 35 times. They sold a total of 332,324 shares worth more than $58,294,947.32. The most recent insider tranaction occured on May, 16th when EVP Charles R Romp sold 349 shares worth more than $66,261.14. Insiders at Seagen own 25.9% of the company. Learn More about insider trades at Seagen.

Information on this page was last updated on 5/16/2023.

Charles R. Romp Insider Trading History at Seagen

See Full Table

Charles R. Romp Buying and Selling Activity at Seagen

This chart shows Charles R. Romp's buying and selling at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seagen Company Overview

Seagen logo
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
Read More

Today's Range

Now: $195.47
Low: $194.68
High: $196.00

50 Day Range

MA: $199.74
Low: $187.64
High: $206.25

2 Week Range

Now: $195.47
Low: $116.08
High: $207.16


606,460 shs

Average Volume

1,535,644 shs

Market Capitalization

$36.65 billion

P/E Ratio


Dividend Yield